Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Lawrence Livermore National Laboratory (LLNL), a part the US Department of Energy's National Nuclear Security Administration, has awarded a second research contract to Trius Therapeutics to develop new antibiotics targeting multi-drug resistant (MDR) bacterial pathogens.
Subscribe to our email newsletter
Under the contract, Trius will receive up to $3m over three years in support of its development efforts.
The current contract aims to create antibiotics that kill bacteria by disrupting cell wall biosynthesis.
Trius chief scientific officer John Finn said the new contract to discover new broad spectrum antibacterial agents that block bacterial cell wall biosynthesis is an exciting complement to their existing programs.